SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

Hawkish commentary from Kevin Warsh at Jackson Hole and rising expectations for interest-rate hikes have driven a broad fintech selloff, with traders largely attributing SoFis weakness to macro and options-related pressure rather than company-specific issues. Bulls argue potential hikes are already reflected in guidance and continue accumulating, while bears cite SoFis rate sensitivity and repeated failures near recent highs.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A bearish BMF short report triggered the selloff, with traders debating its criticisms of SELLASs REGAL trial design, historical controls, dilution and valuation despite no new clinical evidence or adverse company announcement. Bulls call it an unverified short-side hit piece and remain focused on the delayed 80th event and forthcoming Phase 3 topline data, while bears view the prolonged quiet period as a potential warning sign.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Speculation around the approaching earnings report is driving attention, with bulls expecting an earnings beat, potential tariff refunds, and a turnaround under incoming CEO Heidi ONeill to support a short squeeze. Bears remain concerned about weak consumer demand, competition, executive departures, and the risk of another guidance reduction, while Michael Burrys reported accumulation is adding to the debate.

Reading International, Inc. is an entertainment and real estate company, which engages in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through the Cinema Exhibition and Real Estate segments. The Cinema Exhibition segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, City Cinemas, 44 Union Square, and Liberty Theatres brands. The Real Estate segment consists of real estate development and the rental or licensing of retail, commercial and live theater assets. The company was founded by James J. Cotter Sr. in 1999 and is headquartered in New York, NY.

Reading International Inc - Ordinary Shares - Class B

A sharp move in Reading Internationals thinly traded Class B shares has drawn speculation around a low-float short squeeze, with traders citing limited share availability, halts and expanding volume. Some community members also point to an earnings turnaround and the companys real-estate holdings, while others view the move as a speculative pump and warn of selling pressure.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Anticipation of an Anthropic IPO is driving attention, with traders viewing DXYZs sizable Anthropic exposure as a potential rerating catalyst alongside an overdue NAV update. Bullish participants expect higher NAV and renewed pre-IPO interest, while skeptics cite limited transparency, dilution, and uncertainty over the validity of the Anthropic SPV structure.

Boost Run, Inc. is a provider of scalable cloud infrastructure purpose-built for enterprise AI and high-performance computing workloads. The platform delivers GPU compute, CPU nodes, managed Kubernetes orchestration, and shared storage through an intuitive management console and a robust API layer, enabling organizations to provision and scale resources across thousands of nodes in minutes. The company was founded on September 5, 2025 and is headquartered in Northbrook, IL.

Boost Run Inc. - Ordinary Shares - Class A

Boost Run Inc.

A sharp selloff across AI and neocloud stocks, amplified by reports about a potentially paused NVIDIA GPU financing program, hawkish rate expectations, and warrant-related dilution, has driven attention to BRUN. Traders debate whether BRUN was unfairly swept up despite its earnings, contracts, and NVIDIA partner status, while skeptics cite execution, GPU-demand, and capital-raising risks.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

A quarterly earnings beat and stronger-than-expected forward guidance have driven heavy AFRM attention, with bulls emphasizing growth, profitability, and expanding buy-now-pay-later adoption. Traders are divided after the initial surge reversed sharply on heavy volume, citing profit-taking, options positioning, and broader rate concerns, while others view the decline as a temporary sell-the-news reaction.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

Attention centers on reported renewed take-private interest from Irth Capital, reportedly strengthened by backing from Papa Johns largest U.S. franchisee. Traders are divided between expecting a deal or short-covering rally and doubting the rumor, while weak sales, management criticism, and the suspended dividend increase pressure on the board to sell.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

Treasury plans to expand long-duration bond buybacks, potentially using its cash account, have made TLT a focal point as traders debate whether intervention can sustainably lower long-term yields. Bulls anticipate a bond short squeeze, while skeptics argue persistent inflation, heavy borrowing and a potentially hawkish Fed stance could keep rates elevated.

ProShares Trust II - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver is attracting intense community attention as traders debate whether current volatility represents a major buying opportunity or a dangerous trap during ongoing geopolitical instability. Investors are actively discussing the decoupling of silver from its traditional inverse correlation with the dollar and oil, with many tracking COMEX inventory levels and industrial demand while expressing concern over the rapid decay associated with leveraged ETFs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

EXCLUSIVE: Nvidia GPUs Are EssentialBut They Won't Decide Who Wins AI Drug Discovery, Generate CTO Says

Generate Biomedicines CTO says Nvidia GPUs are essential, but data and experimentation will determine AI drug discovery winners.read more...

QUICK SPARK: Nvidia-Backed Biotech Says AI Could Make Biology Programmable

Generate Biomedicines says AI could make biology programmable by generating and testing drug hypotheses at machine scale.read more...

EXCLUSIVE: Nvidia's Biggest Contribution to AI Drug Discovery Isn't Money, Generate CTO Says

Generate Biomedicines co-founder & CTO says Nvidia's biggest contribution to AI drug discovery is technical collaboration, not just capital.read more...

Nvidia CEO Jensen Huang Said AI's 'Most Profound Impact Will Be in Life Sciences.' Does This Bet on a Biotech Stock Prove He Means It?

Key PointsThe chipmaker has active interests in the healthcare market, including a partnership with Eli Lilly and an investment in small biotech Generate Biomedicines...

Cathie Wood Likes That New Stock Smell: 3 IPO Stocks She Bought on Monday

Key PointsCathie Wood added to her positions in Space Exploration, Bullish, and Generate Biomedicines on Monday...

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts

AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts PR Newswire BOSTON, June 22, 2026 Newly Constructed Phase 2 now 100...

A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer

Key PointsHarbourVest initiated 1,722,210 shares of Generate Biomedicines last quarter; the estimated trade size was $21.03 million based on quarterly average prices...

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference

Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire SOMERVILLE, Mass., May 28, 2026 SOMERVILLE, Mass., May 28, 2026 /PRNewswire...

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update PR Newswire SOMERVILLE, Mass., May 7, 2026 SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials...

Generate Biomedicines (NASDAQ:GENB) Hits New 1-Year High  - Should You Buy?

Generate Biomedicines (NASDAQ:GENB) Reaches New 52-Week High - Time to Buy...

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company was founded in 2018, and is headquartered in Somerville, MA.

Generate Biomedicines Inc

Extremely Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

GENB Generate Biomedicines Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest GENB News